The Top Line

September 2, 2022


Listen Later

In Alzheimer’s, three drug candidates capture most of the industry's attention these days, and for good reason. They’re all in late-stage development and have the likes of Biogen, Eisai, Genentech and Eli Lilly backing them. But in this week’s episode, we step away from the big three. The Alzheimer’s Association found that there are 143 drugs in the pipeline. If fully enrolled, these trials would involve 50,575 people and more than 3.8 million participant weeks. We’ll dive into these details and more tidbits from AA’s report.

And that’s not all. As we gear up to publish our annual Fierce 15 report honoring biotechs with the most exciting technologies, we’re also taking the time to look back at our 2012 class of Fierce 15. By now, several companies have fallen off the map, but many others were part of blockbuster deals or continue to plug away at their pipelines. We profile all of them, what they’ve been up to and what’s coming next.

To learn more about topics in this episode: 

  • Beyond headlines and amyloid, the Alzheimer's pipeline chugs along
  • Where are they now? Tracking down 2012's Fierce 15

The Top Line is produced by senior multimedia producer Teresa Carey with managing editor Querida Anderson and senior editors Annalee Armstrong, Ben Adams, Conor Hale and Eric Sagonowsky. The sound engineer is Caleb Hodgson. The stories are by all our “Fierce” journalists. Like and subscribe wherever you listen to your podcasts.

See omnystudio.com/listener for privacy information.

...more
View all episodesView all episodes
Download on the App Store

The Top LineBy Fierce Life Sciences

  • 3.8
  • 3.8
  • 3.8
  • 3.8
  • 3.8

3.8

8 ratings


More shows like The Top Line

View all
WSJ Your Money Briefing by The Wall Street Journal

WSJ Your Money Briefing

1,753 Listeners

The McKinsey Podcast by McKinsey & Company

The McKinsey Podcast

381 Listeners

a16z Podcast by Andreessen Horowitz

a16z Podcast

1,040 Listeners

Exchanges by Goldman Sachs

Exchanges

992 Listeners

Odd Lots by Bloomberg

Odd Lots

1,789 Listeners

Macro Musings with David Beckworth by Mercatus Center at George Mason University

Macro Musings with David Beckworth

375 Listeners

The Long Run with Luke Timmerman by Timmerman Report

The Long Run with Luke Timmerman

122 Listeners

The Readout Loud by STAT

The Readout Loud

318 Listeners

Inside the Strategy Room by McKinsey & Company

Inside the Strategy Room

171 Listeners

Why It Matters by Council on Foreign Relations

Why It Matters

876 Listeners

Business Of Biotech by Ben Comer

Business Of Biotech

88 Listeners

BioCentury This Week by BioCentury

BioCentury This Week

29 Listeners

Raising Health by Andreessen Horowitz, a16z Bio + Health

Raising Health

147 Listeners

Biotech Hangout by Daphne Zohar, Josh Schimmer, Brad Loncar, Tim Opler & more

Biotech Hangout

18 Listeners

Ground Truths by Eric Topol

Ground Truths

51 Listeners